Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits

Neuropharmacology

Volumn 43, Issue 6, 2002, Pages 999-1005

  Weinstock, M ^a   Gorodetsky, E ^a   Wang, R H ^a   Gross, A ^b   Weinreb, O ^b   Youdim, M B H ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Blood pressure; MAO A and B inhibitors; Oral tyramine; Rabbits

Indexed keywords

(N PROPARGYLAMINOINDAN 5 YL)ETHYLMETHYLCARBAMATE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CLORGYLINE; LADOSTIGIL; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; TRANYLCYPROMINE; TYRAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RABBIT;

2-HYDROXYPHENETHYLAMINE; ADMINISTRATION, ORAL; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BLOOD PRESSURE; BRAIN; CLORGYLINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; INDANS; INTESTINES; LIVER; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; RABBITS; SELEGILINE; SEROTONIN; TRANYLCYPROMINE; TYRAMINE;

EID: 0036849156     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00176-4     Document Type: Article

References (30)

1. Amrein R., Allen S.R., Vranesic D., Stable M. Antidepressant drug therapy: associated risks. Journal of Neural Transmission. 26:(Suppl.):1988;73-87.
2. Blackwell B., Marley E. Interactions with cheese and its constituents with monoamine oxidase inhibitors. British Journal of Pharmacology and Chemotherapy. 26:1966;120-141.
3. Blackwell B., Marley E., Price J., Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. British Journal of Psychiatry. 113:1967;349-365.
4. Da Prada M., Zürcher G., Wüthrich I., Haefely W.E. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. Journal of Neural Transmission. 26:(Suppl.):1988;31-56.
5. Dowson J.H. MAO inhibitors in mental disease. Journal of Neural Transmission. 23:(Suppl.):1987;121-138.
6. Edwards J.G. Drug choice in depression. Selective serotonin reuptake inhibitors or tricyclic antidepressants? CNS Drugs. 4:1995;141-159.
7. Finberg J.P.M., Tenne M., Youdim M.B.H. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. British Journal of Pharmacology. 73:1981;65-74.
8. Finberg J.P.M., Tenne M. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. British Journal of Pharmacology. 77:1982;13-21.
9. Holzbauer M., Youdim M.B.H. Physiological control of monoamine oxidases. Usdin E., Weiner N., Youdim M.B.H., The Structure and Function of Monoamine Enzymes. 1977;601-627 Marcel Dekker, New York.
10. Huang W., Chen Y., Shohami E., Weinstock M. Neuroprotective effect of rasagiline, a selective MAO-B inhibitor, against closed head injury in the mouse. European Journal of Pharmacology. 366:1999;127-135.
11. Johnston J.P. Some observation upon a new inhibitor of monoamine oxidase in brain tissue. Biochemical Pharmacology. 17:1968;1285-1297.
12. Levy M.L., Cummings J.L., Fairbanks L.A., Bravi D., Calvani M., Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. American Journal of Psychiatry. 153:1996;1438-1443.
13. Miura H., Naoi M., Nakahara D., Ohta T., Nagatsu T. Effects of moclobemide on forced swimming stress and brain monoamine levels in mice. Pharmacology, Biochemistry and Behavior. 53:1996;469-475.
14. Müller T., Gieschke R., Ziegler W.H. Blood pressure response to tyramine-enriched meal before and during MAO-inhibition in man: influence of dosage regimen. Journal of Neural Transmission. 26:(Suppl.):1988;105-114.
15. Newman S.C. The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample. Journal of Affective Disorders. 52:1999;169-176.
16. Palmer A.M., Stratman G.C., Procter A.W., Bowen D.M. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Annals of Neurology. 23:1988;616-620.
17. Paykel E.S., Rowan P.R., Parker R.R., Bhat A.V. Response to phenelzine and amitriptyline in subtypes of outpatient depression. Archives of General Psychiatry. 39:1982;1041-1049.
18. Paykel E.S. Clinical efficacy of reversible and selective inhibitors of monoamine oxidase in major depression. Acta Psychiatrica Scandinavica. 91:(Suppl. 386):1995;22-27.
19. Porsolt R.D., Bertin A., Blavet N., Deniel M., Jalfre M. Immobility induced by forced swimming in rats: Effects of agents which modify central catecholamine and serotonin activity. European Journal of Pharmacology. 57:1979;201-210.
20. Rabey J.M., Sagi I., Huberman M., Melamed E., Korczyn A., Giladi N., Inzelberg R., Djaldetti R., Klein C., Berecz G. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clinical Neuropharmacology. 23:2000;324-330.
21. Tipton K.F., Houslay M.D., Mantle T.J. The nature and locations of the multiple forms of monoamine oxidase. Monoamine oxidase and its inhibition. Ciba Foundation Symposium 39. 1976;5-31 Elsevier, Amsterdam.
22. Tipton K.F., Youdim M.B.H. The assay of monoamine oxidase activity. Parvez S., Nagatsu T., Nagatsu I., Parvez H., Methods in Biogenic Amine Research. 1983;441-467 Elsevier, Amsterdam.
23. Waldmeier P.C. Amine oxidases and their endogenous substrates. Journal of Neural Transmission. 23:(Suppl.):1987;55-72.
24. Weinstock M., Goren T., Youdim M.B.H. Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Development Research. 50:2000;216-222.
25. Weinstock M., Kirschenbaum-Slager N., Lazarovici P., Bejar C., Youdim M.B.H., Shoham S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Annals of the New York Academy of Science. 939:2001;148-161.
26. Weinstock M., Poltyrev T., Bejar C., Sagi Y., Youdim M.B.H. TV3326, a novel cholinesterase and MAO inhibitor for Alzheimer's disease with co-morbidity of Parkinson's disease and depression. Mizuno Y., Fisher A., Hanin I., Mapping the progress of Alzheimer's and Parkinson's disease. 2000;199-204 Kluwer Academic/Plenum Publishers, New York.
27. Weinstock M., Poltyrev T., Bejar C., Youdim M.B.H. Effect of TV3326, a novel monoamine-oxidase-cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology. 160:2002;318-324.
28. Wong K.P. The conjugation of tyramine with sulphate by liver and intestine of different animals. The Biochemical Journal. 160:1976;491-493.
29. Youdim M.B.H., Gross A., Finberg J.P.M. Rasagiline [N-propyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. British Journal of Pharmacology. 132:2001;500-506.
30. Youdim M.B.H., Wadia A., Tatton W., Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Annals of the New York Academy of Science. 939:2001;450-458.